{{Drugbox
| verifiedrevid = 448120715
| IUPAC_name = Methyl 6-({[(2-chloroethyl)(nitroso)amino]carbonyl}amino)-6-deoxy-α-<small>D</small>-glucopyranoside
| image = Ranimustine (Haworth).svg
| width = 215

<!--Clinical data-->
| tradename = Cymerin
| Drugs.com = {{drugs.com|international|ranimustine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = [[Intravenous therapy|IV]]

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 58994-96-0
| ATC_prefix = L01
| ATC_suffix = AD07
| ATC_supplemental =  
| PubChem = 71741
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = RYH2T97J77
| ChemSpiderID      = 64785

<!--Chemical data-->
| chemical_formula =  
| C=10 | H=18 | Cl=1 | N=3 | O=7 
| molecular_weight = 327.71 g/mol
| smiles = CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CNC(=O)N(CCCl)N=O)O)O)O
| StdInChI = 1S/C10H18ClN3O7/c1-20-9-8(17)7(16)6(15)5(21-9)4-12-10(18)14(13-19)3-2-11/h5-9,15-17H,2-4H2,1H3,(H,12,18)/t5-,6-,7+,8-,9+/m1/s1
| StdInChIKey = AHHFEZNOXOZZQA-ZEBDFXRSSA-N

| synonyms = <small>1-(2-chloroethyl)-1-nitroso-3-([(2''R'',3''S'',4''S'',5''R'',6''S'')-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl)urea</small>
}}

'''Ranimustine''' ([[International Nonproprietary Name|INN]], marketed under the tradename Cymerin; also known as MCNU) is a [[nitrosourea]] [[alkylating antineoplastic agent|alkylating agent]] approved in [[Japan]] for the treatment of chronic myelogenous [[leukemia]]<ref name="pmid2817908">{{cite journal  |vauthors=Kitajima K, Adachi T, Takahashi I, etal |title=[Chemotherapy of chronic myelogenous leukemia—VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis] |language=Japanese |journal=Gan To Kagaku Ryoho |volume=16 |issue=11 |pages=3573–9 |date=November 1989 |pmid=2817908 |doi= |url=}}</ref> and polycythemia vera.<ref name="pmid3196045">{{cite journal  |vauthors=Nagai M, Tasaka T, Kamano H, etal |title=[Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera] |language=Japanese |journal=Gan To Kagaku Ryoho |volume=15 |issue=12 |pages=3267–70 |date=December 1988 |pmid=3196045 |doi= |url=}}</ref>

It has never been filed for [[Food and Drug Administration|FDA]] evaluation in the [[United States]], where it is not marketed.

==References==
{{Reflist}}
* {{ja icon}} [http://di.mt-pharma.co.jp/file/dc/cmr_a.pdf Cymerin サイメリン] (PDF) Mitsubishi Tanabe Pharma. October 2007.

{{Chemotherapeutic agents}}

[[Category:Alkylating antineoplastic agents]]
[[Category:Nitrosamines]]
[[Category:Nitrosoureas]]
[[Category:Ureas]]

{{antineoplastic-drug-stub}}